Initial analyses of Colon Cancer - Specific Antigen (CCSA)-3 and CCSA-4 as colorectal cancer - Associated serum markers

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5600-5605

  Leman, Eddy S ^a   Schoen, Robert E ^b   Weissfeld, Joel L ^b   Cannon, Grant W ^a   Sokoll, Lori J ^a   Chan, Daniel W ^a   Getzenberg, Robert H ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLON CANCER SPECIFIC ANTIGEN 3; COLON CANCER SPECIFIC ANTIGEN 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANTIGEN SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; COLONOSCOPY; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; ANTIGENS, NEOPLASM; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34250815764     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0649     Document Type: Article

References (11)

1. Bond JH. Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas. Semin Gastrointest Dis 2000;11:176-84.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
3. Hardcastle JD, Chamberlain, JO, Robinson, MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
4. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7.
5. Pignone M, Rich M, Teutsch SM, et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:132-41.
6. Trends in screening for colorectal cancer - United States. MMWR - Morbidity and Mortality Weekly Report; 2001. p. 162-6.
7. Konety BR, Getzenberg RH. Nuclear structural proteins as biomarkers of cancer. J Cell Biochem 1999;Suppl 32-3:183-91.
8. Brunagel G, Vietmeier BN, Bauer AJ, et al. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res 2002;62:2437-42.
9. Brunagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclearmatrix protein alterations in human colonic adenomatous polyps. J Cell Biochem 2004;91:365-74.
10. Pepe M. The statistical evaluation of medical tests for classification and prediction. New York: Oxford University Press; 2003.
11. Miller TE, Beausang LA, Winchell LF, et al. Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 1992;52:422-7.